Clinical Trial Update: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial compares ramucirumab plus pembrolizumab versus pembrolizumab alone in PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cyramza (ramucirumab) (ramucirumab)
• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING